Engage Bio
Potent, durable, and redosable non-viral genetic medicines
Monthly revenue–Not shared yet
Rank–Unranked
Last 30 days–Growth in MRR
Revenue per founder–– founders
About Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Discover more startups
Browse the board →MRR
$251K
Last 30 days
-2%
Founder
Jacob Jacquet
MRR
$250K
Last 30 days
0%
Founder
Eugene Zolotarenko
MRR
$250K
Last 30 days
0%
Founder
Valon Asani